AIM: Multiple sclerosis (MS) is a common and heterogeneous CNS inflammatory demyelinating disease. The HLA-DRB1 locus may influence clinical outcome. MS cortical pathology is frequent and correlates with measures of clinical disability, including motoric dysfunction that is a predominant feature of disease progression. The influence of HLA-DRB1*15 on motor cortical pathology is unknown. METHODS: A pathologically confirmed age- and sex-matched HLA-DRB1*15+ (n = 21) and HLA-DRB1*15- (n = 26) MS post-mortem cohort was used for detailed pathologic analyses. For each case, adjacent sections of motor cortex were stained for myelin and inflammation, to evaluate the extent and distribution of motor cortical pathology. A subset of MS cases (n = 42) had spinal cord (SC) pathologic outcome data available for comparison. RESULTS: Motor cortical demyelination was more pronounced in younger cases (r = -0.337, P < 0.05), with MS cases carrying the HLA-DRB1*15 allele driving this effect (r = -0.612, P < 0.01). HLA-DRB1*15+ MS cases had more severe motor cortical parenchymal (P < 0.05), perivascular (P < 0.05) and meningeal (P < 0.05) T-cell inflammation compared to HLA-DRB1*15- cases. HLA-DRB1*15 status significantly influenced the extent of motor cortical microglial burden in both NAGM (P < 0.0001) and lesions (P < 0.01) in MS cases. Relationships between the extent of motor cortical and SC pathology were limited, but when present were primarily driven by HLA-DRB1*15+ cases. CONCLUSION: HLA-DRB1*15 status has a significant association with the extent of inflammation in the MS motor cortex, the extent of demyelination in younger MS cases, and influences relationships between motor cortical and SC pathology.
AIM: Multiple sclerosis (MS) is a common and heterogeneous CNS inflammatory demyelinating disease. The HLA-DRB1 locus may influence clinical outcome. MS cortical pathology is frequent and correlates with measures of clinical disability, including motoric dysfunction that is a predominant feature of disease progression. The influence of HLA-DRB1*15 on motor cortical pathology is unknown. METHODS: A pathologically confirmed age- and sex-matched HLA-DRB1*15+ (n = 21) and HLA-DRB1*15- (n = 26) MS post-mortem cohort was used for detailed pathologic analyses. For each case, adjacent sections of motor cortex were stained for myelin and inflammation, to evaluate the extent and distribution of motor cortical pathology. A subset of MS cases (n = 42) had spinal cord (SC) pathologic outcome data available for comparison. RESULTS: Motor cortical demyelination was more pronounced in younger cases (r = -0.337, P < 0.05), with MS cases carrying the HLA-DRB1*15 allele driving this effect (r = -0.612, P < 0.01). HLA-DRB1*15+ MS cases had more severe motor cortical parenchymal (P < 0.05), perivascular (P < 0.05) and meningeal (P < 0.05) T-cell inflammation compared to HLA-DRB1*15- cases. HLA-DRB1*15 status significantly influenced the extent of motor cortical microglial burden in both NAGM (P < 0.0001) and lesions (P < 0.01) in MS cases. Relationships between the extent of motor cortical and SC pathology were limited, but when present were primarily driven by HLA-DRB1*15+ cases. CONCLUSION: HLA-DRB1*15 status has a significant association with the extent of inflammation in the MS motor cortex, the extent of demyelination in younger MS cases, and influences relationships between motor cortical and SC pathology.
Authors: T Matsushita; L Madireddy; T Sprenger; P Khankhanian; S Magon; Y Naegelin; E Caverzasi; R L P Lindberg; L Kappos; S L Hauser; J R Oksenberg; R Henry; D Pelletier; S E Baranzini Journal: Genes Brain Behav Date: 2015-03-05 Impact factor: 3.449
Authors: Susan J van Rensburg; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Armand V Peeters; Carel J van Heerden; Rajiv T Erasmus; Annalise E Zemlin; Merlisa C Kemp; Mariaan Jaftha; Aye Aye Khine; Felix C V Potocnik; Lindiwe Whati; Penelope Engel-Hills; Ronald van Toorn; Maritha J Kotze Journal: Metab Brain Dis Date: 2021-03-12 Impact factor: 3.584
Authors: Richard L Yates; Jonathan Pansieri; Qizhu Li; Jack S Bell; Sydney A Yee; Jacqueline Palace; Margaret M Esiri; Gabriele C DeLuca Journal: Brain Pathol Date: 2021-12-13 Impact factor: 7.611
Authors: Lukas Simon Enz; Thomas Zeis; Daniela Schmid; Florian Geier; Franziska van der Meer; Guido Steiner; Ulrich Certa; Thomas Martin Christian Binder; Christine Stadelmann; Roland Martin; Nicole Schaeren-Wiemers Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-12-27